Aurobindo Pharma's ANDA filings FY 2019, by therapy
New drug applications for central nervous system (CNS) therapy made up for around 95 of the new drug applications filed by Aurobindo Pharma as of financial year 2019. New drug applications for cardiovascular diseases followed with almost 84 percent of the total ANDAs that year.